IL13 and myeloid leukemia: With approx. 50% of all circulating ILC2 in the blood expressing NKp30, Trabanelli et al. found that myeloid leukemia-derived PGD2 and surface expressed B7-H6 elevated ILC2-derived IL-13 production and synergized in creating an immunosuppressive milieu, fostering the development of monocytic myeloid-derived suppressor cells (M-MDSCs) [77].